Skip to main content
Explore URMC


Deborah A. Mulford, M.D.



Showing all 10 journal articles & 1 books available

Journal Articles

Raza A, Galili N, Smith SE, Godwin J, Boccia RV, Myint H, Mahadevan D, Mulford D, Rarick M, Brown GL, Schaar D, Faderl S, Komrokji RS, List AF, Sekeres M. "A phase 2 randomized multicenter study of 2 extended dosing schedules of oral ezatiostat in low to intermediate-1 risk myelodysplastic syndrome." Cancer.. 2012 Apr 15; 118(8):2138-47. Epub 2011 Sep 01.

Liesveld JL, Rosell KE, Bechelli J, Lu C, Messina P, Mulford D, Ifthikharuddin JJ, Jordan CT, Phillips Ii GL. "Proteasome inhibition in myelodysplastic syndromes and acute myelogenous leukemia cell lines." Cancer investigation.. 2011 Aug 0; 29(7):439-50.

Sekeres MA, Gundacker H, Lancet J, Advani A, Petersdorf S, Liesveld J, Mulford D, Norwood T, Willman CL, Appelbaum FR, List AF. "A phase 2 study of lenalidomide monotherapy in patients with deletion 5q acute myeloid leukemia: Southwest Oncology Group Study S0605." Blood.. 2011 Jul 21; 118(3):523-8. Epub 2011 May 06.

Rosenblat TL, McDevitt MR, Mulford DA, Pandit-Taskar N, Divgi CR, Panageas KS, Heaney ML, Chanel S, Morgenstern A, Sgouros G, Larson SM, Scheinberg DA, Jurcic JG. "Sequential cytarabine and alpha-particle immunotherapy with bismuth-213-lintuzumab (HuM195) for acute myeloid leukemia." Clinical cancer research : an official journal of the American Association for Cancer Research.. 2010 Nov 1; 16(21):5303-11. Epub 2010 Sep 21.

Walker AR, Komrokji RS, Ifthikharuddin J, Messina P, Mulford D, Becker M, Friedberg J, Oliva J, Phillips G, Liesveld JL, Abboud C. "Phase I study of cladribine, cytarabine (Ara-C), granulocyte colony stimulating factor (G-CSF) (CLAG Regimen) and simultaneous escalating doses of imatinib mesylate (Gleevec) in relapsed/refractory AML." Leukemia research.. 2008 Dec 0; 32(12):1830-6. Epub 2008 Jun 20.

Laughlin TS, Becker MW, Liesveld JL, Mulford DA, Abboud CN, Brown P, Rothberg PG. "Rapid method for detection of mutations in the nucleophosmin gene in acute myeloid leukemia." The Journal of molecular diagnostics : JMD.. 2008 Jul 0; 10(4):338-45. Epub 2008 Jun 13.

Mulford, D.; Pandit-Taskar, N.; McDevitt, M.; Finn, R.; Weiss, M.; Apostolidis, C.; Morgenstern, A.; Divgi, C.; Larson, S.; Scheinberg, D., Jurcic, J.;. "Sequential therapy with cytarabine and bismuth-213 (213Bi)-labeled-HuM195 (anti-CD33) for acute myeloid leukemia (AML)". Blood. 2004; .

Mulford, D.; Divgi, C.; McDevitt, M.; Sgouros, G.; Finn, R.; Larson, S.; Apostolidis, C.; Morgenstern, A.; Scheinberg, D.; Jurcic, J.;. "Bismuth-labeled anti-CD33 antibody for elimination of minimal residual disease in acute myeloid leukemia". 10th Conference on Cancer Therapy with Antibodies & Immunoconjugates. 2004; .

Mulford, D.; Maslak, P.; Weiss, M.; Scheinberg, D.; Jurcic, J.;. "Reducing standard postremission chemotherapy in acute promyelocytic leukemia (APL) with risk-adapted therapy." Blood. 2003; : 619a.

Landau, H.; Mulford, D.; Jurcic, J.; Lammanna, N.; Weiss, M.;. "Retrospective study to determine if the presence of trisomy 12 by FISH and cytogenetics is predictive of a slowly-progressive chronic lymphocytic leukemia." `. .

Books & Chapters

Chapter Title: Monoclonal Antibody Therapies of Cancer
Book Title: Cancer Chemotherapy and Biotheraphy
Author List: Scheinberg DA, Mulford DA, Jurcic JG, Junghans RP, Sgouros G.
Published By: Baltimore: Lippincott, Williams, And Wilkins2006